New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 31, 2014
05:16 EDTANACAnacor announces first patient enrolled in Phase 3 Trial of AN2728
Anacor Pharmaceuticals announced that the first patient has been enrolled in the Phase 3 trial of AN2728, a novel boron-based phosphodiesterase-4, or PDE-4, inhibitor, for the topical treatment of mild-to-moderate atopic dermatitis. Atopic dermatitis is a chronic rash characterized by inflammation and itch and affects approximately 10%-20% of infants and young children. The Phase 3 trial consists of two multi-center, double-blind, vehicle-controlled studies which will enroll approximately 750 subjects per study who will be randomized 2:1. Subjects who complete either Phase 3 study will have the option to enroll in a long-term safety trial to evaluate the safety of intermittent use of AN2728 Ointment, 2% for up to 12 months. At least 100 subjects will be enrolled for 12 months and at least 300 subjects will be enrolled for 6 months, during which time subjects will be treated as needed under the direction of the investigator.
News For ANAC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 27, 2015
11:15 EDTANACAnacor management to meet with Jefferies
Subscribe for More Information
August 21, 2015
08:10 EDTANACAnacor: Coalition seeks to invalidate patents for Kerydin
In a regulatory filing, Anacor said that on August 20, a hedge fund -- acting with affiliated parties and proceeding under the name of the Coalition for Affordable Drugs X LLC -- filed petitions with the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office seeking to institute inter partes review proceedings to invalidate Anacor Pharmaceuticals, Inc.'s Orange Book-listed U.S. Patents Nos. 7,582,621 and 7,767,657 covering KERYDIN topical solution, 5%.If one or more of CFAD's IPR petitions are accepted by the PTAB, the Company will have three months to file its preliminary responses. Upon receipt of the Company's preliminary responses, the PTAB will have another three months in which to institute or deny the IPR proceedings. If the IPR proceedings are instituted by the PTAB, CFAD will have an opportunity to challenge the validity of some or all of the claims in the Kerydin Orange Book Patents before the PTAB. The Company is currently reviewing CFAD's IPR petitions and intends to vigorously oppose the institution of the IPR proceedings and, if the IPR proceedings are instituted, to vigorously defend the Kerydin Orange Book Patents.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use